{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:44:14Z","timestamp":1788572654991,"version":"build-2803163510"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Flow cytometric immunophenotyping (FCI) is a fast and sensitive method for characterizing hematolymphoid neoplasms. It is not widely used in the workup of systemic mastocytosis (SM), in part because of the technical challenges and in part because the utility of FCI in assessing mast cells is not well understood. The objectives of this study were to assess the diagnostic utility of FCI in establishing a diagnosis of SM and distinguishing SM from nonneoplastic mast cells and to examine the immunophenotypic findings among SM subtypes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed FCI on bone marrow samples suspicious for SM using a panel consisting of CD2, CD25, CD30, CD45, CD117, and HLA-DR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The cohort included 88 SM cases: 67 without an associated hematologic neoplasm (AHN) (PureSM) and 21 with an AHN (SM-AHN). We also assessed 40 normal\/reactive controls. Overall, FCI was adequate for interpretation in 87 of 88 (99%) cases and detected at least 1 immunophenotypic aberrancy in 100% of SM cases. CD2, CD25, and CD30 were positive in 78%, 98%, and 90% of SM cases vs 0%, 13%, and 13% of cases with normal\/reactive mast cells (P &amp;lt; .0001 for all). Two or 3 abnormalities were observed in 92% of SM cases but not in normal\/reactive mast cells. Among SM cases, SM-AHN showed statistically significant less CD2 (38% vs 91%, P &amp;lt; .0001) and less co-expression of all 3 aberrant markers (CD2, CD25, and CD30 positive in 38% vs 86% of cases; P &amp;lt; .0001) than PureSM. Immunohistochemical analysis showed consistently weaker or focal expression of CD2, CD25, and CD30 than FCI, with CD2 and CD30 being falsely negative in 40% and 50% cases, respectively. A KIT D816V mutation was detected in 67% of PureSM cases and 76% of SM-AHN cases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Flow cytometric immunophenotyping is a quick, sensitive, high-yield tool for evaluating the immunophenotype of mast cells. An abnormal FCI finding should prompt careful histologic evaluation and sensitive KIT D816V mutation testing to address the possibility of SM. CD2, CD25, and CD30 are important markers for the detection of immunophenotypic aberrancy of mast cells, and their frequencies of aberrancy differ across SM subtypes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqad187","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T14:55:30Z","timestamp":1708354530000},"page":"598-608","source":"Crossref","is-referenced-by-count":6,"title":["Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis"],"prefix":"10.1093","volume":"161","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7117-6046","authenticated-orcid":false,"given":"Okechukwu Valentine","family":"Nwogbo","sequence":"first","affiliation":[{"name":"Pathology & Laboratory Medicine Division, University of Texas MD Anderson Cancer Center , Houston, TX , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, Division of Pathology-Lab Medicine Division, University of Texas MD Anderson Cancer Center , Houston, TX , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, Division of Pathology-Lab Medicine Division, University of Texas MD Anderson Cancer Center , Houston, TX , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, Division of Pathology-Lab Medicine Division, University of Texas MD Anderson Cancer Center , Houston, TX , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8467-5464","authenticated-orcid":false,"given":"Roberto N","family":"Miranda","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, Division of Pathology-Lab Medicine Division, University of Texas MD Anderson Cancer Center , Houston, TX , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[{"name":"Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center , Houston, TX , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Young","family":"Ok","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, Division of Pathology-Lab Medicine Division, University of Texas MD Anderson Cancer Center , Houston, TX , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L","family":"Jorgensen","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, Division of Pathology-Lab Medicine Division, University of Texas MD Anderson Cancer Center , Houston, TX , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, Division of Pathology-Lab Medicine Division, University of Texas MD Anderson Cancer Center , Houston, TX , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa A","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, Division of Pathology-Lab Medicine Division, University of Texas MD Anderson Cancer Center , Houston, TX , US"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"2024060305520445900_CIT0001","first-page":"1420","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume-title":"Blood.","author":"Valent","year":"2017"},{"key":"2024060305520445900_CIT0002","first-page":"1703","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume-title":"Leukemia.","author":"Khoury","year":"2022"},{"key":"2024060305520445900_CIT0003","first-page":"1200","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: integrating morphological, clinical, and genomic data","volume-title":"Blood.","author":"Arber","year":"2022"},{"key":"2024060305520445900_CIT0004","first-page":"560","article-title":"Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia","volume-title":"Am J Clin Pathol.","author":"Krokowski","year":"2005"},{"key":"2024060305520445900_CIT0005","first-page":"493","article-title":"Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis","volume-title":"Am J Clin Pathol.","author":"Reichard","year":"2015"},{"key":"2024060305520445900_CIT0006","first-page":"780","article-title":"CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis","volume-title":"Histopathology.","author":"Morgado","year":"2013"},{"key":"2024060305520445900_CIT0007","first-page":"e10642","article-title":"Prevalence of CD30 immunostaining in neoplastic mast cells: a retrospective immunohistochemical study","volume-title":"Medicine (Baltimore).","author":"Russano de Paiva Silva","year":"2018"},{"key":"2024060305520445900_CIT0008","first-page":"297","article-title":"Flow cytometry in mastocytosis: utility as a diagnostic and prognostic tool","volume-title":"Immunol Allergy Clin North Am.","author":"S\u00e1nchez-Mu\u00f1oz","year":"2014"},{"key":"2024060305520445900_CIT0009","first-page":"1210","article-title":"Flow cytometric immunophenotypic analysis of systemic mastocytosis involving bone marrow","volume-title":"Arch Pathol Lab Med.","author":"Jabbar","year":"2014"},{"key":"2024060305520445900_CIT0010","first-page":"333","article-title":"Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders","volume-title":"Methods Cell Biol.","author":"S\u00e1nchez-Mu\u00f1oz","year":"2011"},{"key":"2024060305520445900_CIT0011","first-page":"1735","article-title":"High-sensitivity flow cytometric analysis of mast cell clustering in systemic mastocytosis: a quantitative and statistical analysis","volume-title":"Leuk Lymphoma.","author":"Pozdnyakova","year":"2015"},{"key":"2024060305520445900_CIT0012","first-page":"331","article-title":"Identification and immunophenotypic characterization of normal and pathological mast cells","volume-title":"Methods Mol Biol.","author":"Morgado","year":"2020"},{"key":"2024060305520445900_CIT0013","first-page":"160","article-title":"Myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangements of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2","volume-title":"Am J Clin Pathol.","author":"Pozdnyakova","year":"2021"},{"key":"2024060305520445900_CIT0014","first-page":"128","article-title":"Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders","volume-title":"Semin Hematol.","author":"Gotlib","year":"2012"},{"key":"2024060305520445900_CIT0015","first-page":"1540","article-title":"Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms","volume-title":"Blood Adv.","author":"Patel","year":"2019"},{"key":"2024060305520445900_CIT0016","first-page":"405","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume-title":"Genet Med.","author":"Richards","year":"2015"},{"key":"2024060305520445900_CIT0017","first-page":"586","article-title":"Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)","volume-title":"J Pathol.","author":"Sotlar","year":"2010"},{"key":"2024060305520445900_CIT0018","first-page":"219","article-title":"Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chromosomal abnormalities in SM and AHNMD components","volume-title":"Am J Hematol.","author":"Wang","year":"2013"},{"key":"2024060305520445900_CIT0019","first-page":"3769","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies","volume-title":"Blood.","author":"Pardanani","year":"2009"},{"key":"2024060305520445900_CIT0020","first-page":"1286","article-title":"The International Consensus Classification of eosinophilic disorders and systemic mastocytosis","volume-title":"Am J Hematol.","author":"Wang","year":"2023"},{"key":"2024060305520445900_CIT0021","first-page":"180","article-title":"Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay","volume-title":"J Mol Diagn.","author":"Kristensen","year":"2011"},{"key":"2024060305520445900_CIT0022","first-page":"387","article-title":"Expression of CD2 and CD25 on mast cell populations can be seen outside the setting of systemic mastocytosis","volume-title":"Cytometry B Clin Cytom.","author":"Cherian","year":"2016"},{"key":"2024060305520445900_CIT0023","first-page":"535","article-title":"Flow cytometric analysis of normal and neoplastic mast cells: role in diagnosis and follow-up of mast cell disease","volume-title":"Immunol Allergy Clin North Am.","author":"Escribano","year":"2006"},{"key":"2024060305520445900_CIT0024","first-page":"1","article-title":"Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA)","volume-title":"Cytometry B Clin Cytom.","author":"Escribano","year":"2004"},{"key":"2024060305520445900_CIT0025","first-page":"168","article-title":"Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis","volume-title":"J Allergy Clin Immunol.","author":"\u00c1lvarez-Twose","year":"2016"},{"key":"2024060305520445900_CIT0026","first-page":"e4934","article-title":"Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: a case report","volume-title":"Medicine (Baltimore).","author":"Huang","year":"2016"},{"key":"2024060305520445900_CIT0027","first-page":"516","article-title":"Immunophenotyping in systemic mastocytosis diagnosis: \u201cCD25 positive\u201d alone is more informative than the \u201cCD25 and\/or CD2\u201d WHO criterion","volume-title":"Mod Pathol.","author":"Morgado","year":"2012"},{"key":"2024060305520445900_CIT0028","first-page":"440","article-title":"Treatment-free remission in FIP1L1-PDGFRA-positive myeloid\/lymphoid neoplasms with eosinophilia after imatinib discontinuation","volume-title":"Blood Adv.","author":"Metzgeroth","year":"2020"},{"key":"2024060305520445900_CIT0029","first-page":"514","article-title":"Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume-title":"J Allergy Clin Immunol.","author":"Escribano","year":"2009"},{"key":"2024060305520445900_CIT0030","first-page":"1269","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume-title":"J Allergy Clin Immunol.","author":"Alvarez-Twose","year":"2010"},{"key":"2024060305520445900_CIT0031","first-page":"1157","article-title":"Evaluation of the WHO criteria for the classification of patients with mastocytosis","volume-title":"Mod Pathol.","author":"S\u00e1nchez-Mu\u00f1oz","year":"2011"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/161\/6\/598\/57526356\/aqad187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/161\/6\/598\/57526356\/aqad187.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T14:31:10Z","timestamp":1717425070000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/161\/6\/598\/7610492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,2,19]]},"published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqad187","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,1]]},"published":{"date-parts":[[2024,2,19]]}}}